Replicor in the News

Presentation of Replicor’s clinical data at major Liver Disease conferences continues to generate interest in the press on the effects of NAPs in patients infected with HBV and HDV. Links to these articles are found below.

18.06.2018 Combination HBV therapy shows functional control 24 weeks after cessation Healio link
29.11.2017 REP 2139 combination therapy leads to functional control of hepatitis B virus InfoHep link
28.11.2017 Treating viral hepatitis Pan European Networks link
24.10.2017 Tiny hep B drug combo study touts potential of a ‘functional cure’ at little-known Replicor Endpoints News link
24.10.2017 Most patients achieve control of HBV with combined interferon therapy Healio link
23.10.2017 Replicor HBV Combo Leads to Functional Control BioCentury link
09.10.2017 Combined interferon therapy safe, tolerable in HBV/HDV coinfection Healio link
01.2017 Highlights in Hepatitis B Virus Treatment From the 2016 Annual Meeting of the American Association for the Study of Liver Diseases Gastroenterology & Hepatology (Vol 13, Issue 1) link
27.11.2016 Nucleic acid polymers reduce HBsAg levels and improve control of hepatitis B virus InfoHep link
World Hepatitis Alliance link
HIV and Hepatitis link
17.11.2016 Novel Treatment Could Lead to Functional Control of Hep B Medscape link
16.11.2016 Infusion-Based Therapies Show Promise in HBV – early results with REP 2139 and REP 2165 suggest clearance of surface antigen MedPage Today link
15.11.2016 REP-2165, REP-2139 show efficacy for HBV when combined with TDF, PEG-IFN Healio link
15.11.2015 AASLD 2015: REP 2139 Shows Promise for People with Hepatitis B and Hepatitis Delta Coinfection HIV and Hepatitis link
15.5.2015 Nucleic acid polymer REP 2139-Ca shows promising activity against hepatitis B and hepatitis delta InfoHep link